Serum tissue polypeptide antigen (TPA) in thyroid cancer

Area of Science:

• Oncology
• Biochemistry
• Medical Diagnostics

Background:

• Thyroid cancer management relies on accurate monitoring for recurrence and metastasis.
• Established tumor markers like thyroglobulin (Tg) and carcinoembryonic antigen (CEA) have limitations in certain thyroid cancer types.
• Tissue polypeptide antigen (TPA) is a less explored biomarker in thyroid malignancies.

Purpose of the Study:

• To evaluate the utility of serum TPA as a humoral marker in various types of thyroid cancer.
• To compare TPA performance against established markers (CEA, Tg, CT) in post-thyroidectomy patients.
• To identify TPA's potential role in the follow-up of undifferentiated, dedifferentiated, and medullary thyroid carcinomas.

Main Methods:

• Radioimmunoassays were used to measure serum levels of TPA, CEA, CT, and Tg.
• 174 patients with diverse thyroid cancer types, post-thyroidectomy, were included in the study.
• Serum marker levels were correlated with clinical status, including local invasion and distant metastases.

Main Results:

• Elevated TPA was found in most patients with undifferentiated thyroid cancer or lymphosarcoma with metastases (12/13).
• In previously differentiated thyroid cancer with dedifferentiated metastases, TPA was elevated in 14/15 patients.
• Serum calcitonin (CT) remained the most sensitive marker for medullary thyroid carcinoma, but TPA was also elevated in most of these cases.
• TPA levels were generally normal in well-differentiated thyroid cancer, irrespective of metastases.

Conclusions:

• Serum TPA serves as a novel humoral marker for monitoring undifferentiated and dedifferentiated thyroid carcinomas.
• TPA can be a valuable additional marker for medullary thyroid carcinoma surveillance.
• These findings suggest TPA's expanded role in the comprehensive management of challenging thyroid cancer subtypes.